NaviFUS Corporation AI Stock Analysis
NaviFUS Corporation (6872) AI Stock Analysis
NaviFUS Corporation
(TPEx:6872)
The score is held down primarily by financial performance: revenue fell more than 40%, gross margin turned negative, losses widened to NT$148 million, and free cash outflow hit a record NT$139 million, with no visible path to breakeven. Technicals reinforce the caution, as the stock trades below all key moving averages with negative MACD and weak momentum readings. Valuation offers no support given negative earnings and no dividend. The one meaningful strength is a nearly debt-free balance sheet with NT$556 million of equity, which funds several years of runway, but the ongoing burn makes additional capital raises and dilution a real risk. This remains a speculative, milestone-driven story rather than a fundamentally supported investment.
NaviFUS Corporation (6872) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.29B
- Dividend Yield
- ―
- Average Volume (3M)
- 179.96K
- Price to Earnings (P/E)
- -8.7
- Beta (1Y)
- 0.33
- Revenue Growth
- 42.14%
- EPS Growth
- -19.74%
- Country
- TW
- Employees
- 20
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
NaviFUS Corporation Business Overview & Revenue Model
Company Description
NaviFUS Corporation operates within the medical device sector, specializing in the development and commercialization of advanced focused ultrasound (FUS) technologies tailored for neurological applications. The company's primary offering is NaviFUS,...
NaviFUS Corporation Financial Statement Overview
Summary
NaviFUS is a pre-commercial, clinical-stage medical device company with deeply negative fundamentals. Revenue collapsed roughly 43% to NT$10.5 million, gross margin turned negative (-27%), and the net loss widened to NT$148 million — more than 14 times revenue. Cash burn is accelerating, with operating cash flow at about -NT$91 million and free cash flow at -NT$139 million, the largest outflow in company history. The sole offset is a fortress balance sheet: NT$556 million of equity, just NT$20 million of debt (debt-to-equity of 0.04), and equity that grew despite losses, providing a few years of runway. However, return on equity of approximately -27% is worsening, and future equity raises and dilution appear likely.
Income Statement
9Very NegativeBalance Sheet
62PositiveCash Flow
8Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.25M | 10.48M | 27.53M | 22.48M | 19.53M | 0 |
| Gross Profit | 3.50M | -2.79M | 9.68M | 11.83M | 16.49M | -9.49M |
| EBITDA | -143.21M | -133.30M | -77.03M | -55.80M | -53.84M | -73.14M |
| Net Income | -151.30M | -148.46M | -95.13M | -65.73M | -63.59M | -82.80M |
Balance Sheet | ||||||
| Total Assets | 571.51M | 635.99M | 546.69M | 490.54M | 524.07M | 589.92M |
| Cash, Cash Equivalents and Short-Term Investments | 375.47M | 436.56M | 374.85M | 373.58M | 465.13M | 544.62M |
| Total Debt | 16.38M | 20.18M | 27.53M | 32.69M | 190.00K | 2.46M |
| Total Liabilities | 75.48M | 70.61M | 54.04M | 53.40M | 21.19M | 25.88M |
| Stockholders Equity | 485.99M | 555.64M | 481.50M | 423.00M | 484.95M | 546.44M |
Cash Flow | ||||||
| Free Cash Flow | -98.62M | -138.85M | -133.87M | -88.14M | -81.58M | -60.76M |
| Operating Cash Flow | -78.28M | -91.24M | -77.71M | -48.69M | -57.36M | -52.11M |
| Investing Cash Flow | 530.00K | -94.28M | -58.08M | -15.76M | -24.91M | -53.33M |
| Financing Cash Flow | -7.39M | 210.31M | 143.02M | -3.59M | -2.27M | 294.56M |
NaviFUS Corporation Peers Comparison
Overall Rating
TW:416161Neutral
TW:410945Neutral- TW:687240Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4161 | 61Neutral | TWD 1.22B | 11.45 | ― | 3.32% | 7.54% | 35.87% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4109 | 45Neutral | TWD 1.21B | 256.25 | ― | 1.95% | 13.00% | 902.22% |
| TW:6872 | 40Underperform | TWD 1.26B | -8.71 | ― | ― | 42.14% | -19.74% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6872 | NaviFUS Corporation | 18.65 | -1.35 | -6.75% | |
| TW:4109 | Jia Jie Biomedical Co., Ltd. | 10.25 | -5.46 | -34.76% | |
| TW:4161 | Bioptik Technology, Inc. | 21.10 | -4.55 | -17.73% | |
| TW:6543 | Perfect Medical Industry Co., Ltd. | 16.55 | -11.20 | -40.36% | |
| TW:6847 | PuriBlood Medical Co.,Ltd. | 70.40 | -2.46 | -3.38% | |
| TW:7814 | Horien Biochemical Technology Co., Ltd. | 27.30 | -13.00 | -32.26% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026